^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    HemeScreen™ Panel

    Company:
    Precipio
    Type:
    CE Marked
    Related tests:

    Details

    Evidence
    News
    Precipio has developed a proprietary hematologic malignancy screening panel. The screening panel currently includes JAK2 (V617F), JAK2 Exon 12, MPL & CALR.
    Cancer:
    Acute Myelogenous Leukemia, Chronic Myeloid Leukemia, Hematological Malignancies, Myelodysplastic Syndrome
    Gene:
    CALR (Calreticulin), JAK2 (Janus kinase 2), MPL (MPL Proto-Oncogene, Thrombopoietin Receptor)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    05/24/22
    CLL
    -
    CE
    AML
    -
    MDS
    -